{"protocolSection":{"identificationModule":{"nctId":"NCT02091739","orgStudyIdInfo":{"id":"MRZ60201_3090_1"},"secondaryIdInfos":[{"id":"2012-005539-10","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Merz Pharmaceuticals GmbH","class":"INDUSTRY"},"briefTitle":"Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions","officialTitle":"Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Multicenter Study, With an Extension Period of Dose-blinded Active Treatment, to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions","acronym":"SIAXI"},"statusModule":{"statusVerifiedDate":"2018-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-04"},"primaryCompletionDateStruct":{"date":"2015-08","type":"ACTUAL"},"completionDateStruct":{"date":"2016-11","type":"ACTUAL"},"studyFirstSubmitDate":"2014-03-18","studyFirstSubmitQcDate":"2014-03-18","studyFirstPostDateStruct":{"date":"2014-03-19","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-01-15","resultsFirstSubmitQcDate":"2018-01-15","resultsFirstPostDateStruct":{"date":"2018-02-15","type":"ACTUAL"},"dispFirstSubmitDate":"2016-07-26","dispFirstSubmitQcDate":"2016-07-26","dispFirstPostDateStruct":{"date":"2016-07-28","type":"ESTIMATED"},"lastUpdateSubmitDate":"2018-02-27","lastUpdatePostDateStruct":{"date":"2018-03-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merz Pharmaceuticals GmbH","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The objective of this study is to investigate the efficacy and safety of two different dose levels of NT 201 (75 U or 100 U per cycle), compared with placebo, in reducing the salivary flow rate, and the severity and frequency of chronic troublesome sialorrhea that occurs as a result of various neurological conditions in adult subjects."},"conditionsModule":{"conditions":["Chronic Troublesome Sialorrhea","Parkinson's Disease","Post-stroke","Traumatic Brain Injury"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":184,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"IncobotulinumtoxinA (Xeomin) (100 Units)","type":"EXPERIMENTAL","description":"* Main period (1 treatment cycle): Subjects to receive 100 Units.\n* Extension period (3 treatment cycles): Subjects to receive 100 Units per treatment cycle.\n* Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)","interventionNames":["Drug: IncobotulinumtoxinA (100 Units)"]},{"label":"IncobotulinumtoxinA (Xeomin) (75 Units)","type":"EXPERIMENTAL","description":"* Main period (1 treatment cycle): Subjects to receive 75 Units.\n* Extension period (3 treatment cycles): Subjects to receive 75 Units per treatment cycle.\n* Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)","interventionNames":["Drug: IncobotulinumtoxinA (75 Units)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"* Main period (1 treatment cycle): Subjects to receive placebo injection.\n* Extension period (3 treatment cycles): Subjects will be randomized to receive either 75 or 100 Units IncobotulinumtoxinA per treatment cycle.\n* Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"IncobotulinumtoxinA (100 Units)","description":"Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).","armGroupLabels":["IncobotulinumtoxinA (Xeomin) (100 Units)"],"otherNames":["Xeomin","NT 201","Botulinum toxin type A (150 kiloDalton), free from complexing proteins"]},{"type":"DRUG","name":"IncobotulinumtoxinA (75 Units)","description":"Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).","armGroupLabels":["IncobotulinumtoxinA (Xeomin) (75 Units)"],"otherNames":["Xeomin","NT 201","Botulinum toxin type A (150 kiloDalton), free from complexing proteins"]},{"type":"DRUG","name":"Placebo","description":"Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"MP: Change From Baseline in Unstimulated Salivary Flow (uSFR) Rate at Week 4","description":"uSFR was assessed by weighing of dental rolls soaked with saliva over 5 minutes and then procedure was repeated after 30 minutes and the average of the 2 results for flow rate was calculated.","timeFrame":"Baseline and Week 4"},{"measure":"MP: Participant's Global Impression of Change Scale (GICS) at Week 4","description":"The GICS was used to measure the impression of change due to treatment. The response option was a common 7-point Likert scale that ranged from -3 = very much worse to +3 = very much improved and was applicable for participant and caregiver. If the participant was not able to answer then carer's rating was to be recorded instead of participant's rating and the participant's rating was left blank.","timeFrame":"Week 4"}],"secondaryOutcomes":[{"measure":"MP: Change From Baseline in Unstimulated Salivary Flow (uSFR) Rate at Week 8 and 12","description":"uSFR was assessed by weighing of dental rolls soaked with saliva over 5 minutes and then procedure was repeated after 30 minutes and the average of the 2 results for flow rate was calculated.","timeFrame":"Baseline, Week 8 and 12"},{"measure":"MP: Global Impression of Change Scale (GICS) at Week 1, 2, 8 and 12","description":"The GICS was used to measure the investigator's impression of change due to treatment. The response option was a common 7-point Likert scale that ranged from -3 = very much worse to +3 = very much improved and was applicable for participant and caregiver. If the participant was not able to answer then carer's rating was to be recorded instead of participant's rating and the participant's rating was left blank.","timeFrame":"Week 1, 2, 8, and 12"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Documented diagnosis of the basic neurological condition associated with sialorrhea (as above, (i), (ii) or (iii); with onset at least 6 months before screening).\n* Chronic troublesome sialorrhea related to parkinsonism or stroke or traumatic brain injury (for at least 3 months) at screening, defined as the presence of all of the following, at screening and at baseline and for at least the 3 months before screening (where retrospective response to questionnaires is impossible, a statement of equivalent severity will suffice):\n\n  1. A Drooling Severity and Frequency Scale \\[DSFS\\] sum score of at least 6 points and\n  2. A score of at least 2 points for each item of the DSFS and\n  3. A score of at least 3 points on the modified Radboud Oral Motor Inventory for Parkinson's Disease \\[mROMP\\], Section 'III Drooling', Item A).\n* A score of at most 2 points on the mROMP Section 'II Swallowing Symptoms' Item A) and a score of at most 3 points on Item C), at screening and at baseline.\n\nExclusion Criteria:\n\n* Non-neurological secondary causes of sialorrhea.\n* Unstable concomitant medication influencing sialorrhea (such as anticholinergics for the treatment of parkinsonism; dosages of these medications must have been stable for at least 4 weeks before study entry, i.e. screening, and must be planned to remain stable during the course of the study.\n* Recent (i.e., four weeks) drug treatment for sialorrhea.\n* History of recurrent aspiration pneumonia.\n* Extremely poor dental/oral condition as assessed by a qualified dentist.\n* Recent (i.e., one year for sialorrhea, 14 weeks for other indications) treatment with - or known hypersensitivity to - Botulinum toxin, or known hypersensitivity to any ingredient of the study preparation.\n* Recent (i.e., four weeks) changes in anti-parkinsonian medication.\n* Previous or planned surgery or irradiation to control sialorrhea.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Merz Medical Expert","affiliation":"Merz Pharmaceuticals GmbH","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Merz investigational site #049172","city":"Bonn","zip":"53105","country":"Germany","geoPoint":{"lat":50.73438,"lon":7.09549}},{"facility":"Merz Investigational Site #049335","city":"Gera","zip":"07551","country":"Germany","geoPoint":{"lat":50.88029,"lon":12.08187}},{"facility":"Merz Investigational Site #049337","city":"Haag i.OB","zip":"83527","country":"Germany"},{"facility":"Merz Investigational Site #049072","city":"Munich","zip":"80804","country":"Germany","geoPoint":{"lat":48.13743,"lon":11.57549}},{"facility":"Merz Investigational Site #049148","city":"Munich","zip":"81675","country":"Germany","geoPoint":{"lat":48.13743,"lon":11.57549}},{"facility":"Merz Investigational Site #049300","city":"NÃ¼mbrecht","zip":"51588","country":"Germany","geoPoint":{"lat":50.90425,"lon":7.54068}},{"facility":"Merz Investigational Site #049303","city":"Regensburg","zip":"93053","country":"Germany","geoPoint":{"lat":49.01513,"lon":12.10161}},{"facility":"Merz investigational site #049348","city":"Stadtroda","zip":"07646","country":"Germany","geoPoint":{"lat":50.85684,"lon":11.72677}},{"facility":"Merz Investigational Site #049143","city":"Ulm","zip":"89081","country":"Germany","geoPoint":{"lat":48.39841,"lon":9.99155}},{"facility":"Merz Investigational Site #049333","city":"Wolfach","zip":"77709","country":"Germany","geoPoint":{"lat":48.29319,"lon":8.2158}},{"facility":"Merz Investigational Site #049302","city":"Wuerzburg","zip":"97080","country":"Germany","geoPoint":{"lat":49.79391,"lon":9.95121}},{"facility":"Merz investigational site #048068","city":"Bydgoszcz","zip":"85-015","country":"Poland","geoPoint":{"lat":53.1235,"lon":18.00762}},{"facility":"Merz Investigational Site #048088","city":"Bydgoszcz","zip":"85-080","country":"Poland","geoPoint":{"lat":53.1235,"lon":18.00762}},{"facility":"Merz Investigational Site #048029","city":"Gdansk","zip":"80-254","country":"Poland","geoPoint":{"lat":54.35205,"lon":18.64637}},{"facility":"Merz investigational site #048074","city":"Gdansk","zip":"80-546","country":"Poland","geoPoint":{"lat":54.35205,"lon":18.64637}},{"facility":"Merz investigational site #048078","city":"Jaworzno","zip":"43-600","country":"Poland","geoPoint":{"lat":50.20528,"lon":19.27498}},{"facility":"Merz investigational site #048076","city":"Katowice","zip":"40-097","country":"Poland","geoPoint":{"lat":50.25841,"lon":19.02754}},{"facility":"Merz investigational site #048077","city":"Katowice","zip":"40-097","country":"Poland","geoPoint":{"lat":50.25841,"lon":19.02754}},{"facility":"Merz investigational Site #048067","city":"Kielce","zip":"25-103","country":"Poland","geoPoint":{"lat":50.87033,"lon":20.62752}},{"facility":"Merz investigational site #048059","city":"Krakow","zip":"30-539","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Merz investigational site #048031","city":"Krakow","zip":"31-505","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Merz Investigational Site #048087","city":"Krakow","zip":"31-530","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Merz Investigational Site #048022","city":"Lodz","zip":"90-130","country":"Poland","geoPoint":{"lat":51.75,"lon":19.46667}},{"facility":"Merz investigational site #048070","city":"Lublin","zip":"20-718","country":"Poland","geoPoint":{"lat":51.25,"lon":22.56667}},{"facility":"Merz investigational site #048085","city":"Lublin","zip":"30-539","country":"Poland","geoPoint":{"lat":51.25,"lon":22.56667}},{"facility":"Merz investigational site #048072","city":"Lubon","zip":"62-030","country":"Poland","geoPoint":{"lat":52.34705,"lon":16.89267}},{"facility":"Merz Investigational Site #048075","city":"Sandomierz","zip":"27-600","country":"Poland","geoPoint":{"lat":50.68265,"lon":21.74898}},{"facility":"Merz Investigational Site #048086","city":"Torun","zip":"87-100","country":"Poland","geoPoint":{"lat":53.01375,"lon":18.59814}},{"facility":"Merz investigational site #048065","city":"Warszawa","zip":"00-453","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Merz investigational site #048056","city":"Warszawa","zip":"02-097","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Merz investigational site #048064","city":"Warszawa","zip":"03-242","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}}]},"referencesModule":{"references":[{"pmid":"31794936","type":"DERIVED","citation":"Jost WH, Friedman A, Michel O, Oehlwein C, Slawek J, Bogucki A, Ochudlo S, Banach M, Pagan F, Flatau-Baque B, Dorsch U, Csikos J, Blitzer A. Long-term incobotulinumtoxinA treatment for chronic sialorrhea: Efficacy and safety over 64 weeks. Parkinsonism Relat Disord. 2020 Jan;70:23-30. doi: 10.1016/j.parkreldis.2019.11.024. Epub 2019 Nov 26."},{"pmid":"30918101","type":"DERIVED","citation":"Jost WH, Friedman A, Michel O, Oehlwein C, Slawek J, Bogucki A, Ochudlo S, Banach M, Pagan F, Flatau-Baque B, Csikos J, Cairney CJ, Blitzer A. SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea. Neurology. 2019 Apr 23;92(17):e1982-e1991. doi: 10.1212/WNL.0000000000007368. Epub 2019 Mar 27."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 216 participants were screened for the study, of which 184 participants were randomized and treated in the Main Period (MP) of the study. A total of 173 participants who completed the MP, entered the 2 treatment arms of the Extension Period (EP) of the study.","recruitmentDetails":"The study was conducted at 12 sites in Poland and Germany.","groups":[{"id":"FG000","title":"Placebo","description":"Participants received one injection session of overall 2.0 milliliter (mL) placebo matched to the volume of incobotulinumtoxinA via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 in the MP."},{"id":"FG001","title":"MP: IncobotulinumtoxinA (Xeomin) (75 Units)","description":"Participants received one injection session of overall 2.0 mL incobotulinumtoxinA containing 75 units via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 in the MP."},{"id":"FG002","title":"MP: IncobotulinumtoxinA (Xeomin) (100 Units)","description":"Participants received one injection session of overall 2.0 mL incobotulinumtoxinA containing 100 units via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 in the MP."},{"id":"FG003","title":"EP: IncobotulinumtoxinA (Xeomin) (75 Units)","description":"Participants received overall 2.0 mL incobotulinumtoxinA containing 75 units via bilateral intraglandular injection into the parotid and submandibular glands at each of the three injection sessions in the EP."},{"id":"FG004","title":"EP: IncobotulinumtoxinA (Xeomin) (100 Units)","description":"Participants received overall 2.0 mL incobotulinumtoxinA containing 100 units via bilateral intraglandular injection into the parotid and submandibular glands at each of the three injection sessions in the EP."}],"periods":[{"title":"MP: 16 Weeks","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"36"},{"groupId":"FG001","numSubjects":"74"},{"groupId":"FG002","numSubjects":"74"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"69"},{"groupId":"FG002","numSubjects":"72"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]}]},{"title":"EP: 48 Weeks","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"84"},{"groupId":"FG004","numSubjects":"89"}]},{"type":"COMPLETED","comment":"Participants who completed the MP (n=173), entered the 2 treatment arms of the EP of the study.","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"76"},{"groupId":"FG004","numSubjects":"75"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"8"},{"groupId":"FG004","numSubjects":"14"}]}],"dropWithdraws":[{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"2"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"6"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"6"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The Full analysis set (FAS) is the subset of participants who were treated and had at least the baseline value of unstimulated salivary flow (uSFR).","groups":[{"id":"BG000","title":"MP: Placebo","description":"Participants received one injection session of overall 2.0 mL placebo matched to the volume of incobotulinumtoxinA via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 in the MP."},{"id":"BG001","title":"MP: IncobotulinumtoxinA (Xeomin) (75 Units)","description":"Participants received one injection session of overall 2.0 mL incobotulinumtoxinA containing 75 units via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 in the MP."},{"id":"BG002","title":"MP: IncobotulinumtoxinA (Xeomin) (100 Units)","description":"Participants received one injection session of overall 2.0 mL incobotulinumtoxinA containing 100 units via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 in the MP."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"74"},{"groupId":"BG002","value":"74"},{"groupId":"BG003","value":"184"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"28"},{"groupId":"BG003","value":"77"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"46"},{"groupId":"BG003","value":"107"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"54"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"50"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"130"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"74"},{"groupId":"BG002","value":"73"},{"groupId":"BG003","value":"183"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"74"},{"groupId":"BG002","value":"73"},{"groupId":"BG003","value":"183"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kilogram (kg)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"80.6","spread":"16.4"},{"groupId":"BG001","value":"78.4","spread":"17.1"},{"groupId":"BG002","value":"79.8","spread":"14"},{"groupId":"BG003","value":"79.4","spread":"15.7"}]}]}]},{"title":"Body Mass Index (BMI)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kilogram per square meter (kg/m^2)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"28.5","spread":"6"},{"groupId":"BG001","value":"26.7","spread":"5.2"},{"groupId":"BG002","value":"27.7","spread":"3.8"},{"groupId":"BG003","value":"27.5","spread":"4.9"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"MP: Change From Baseline in Unstimulated Salivary Flow (uSFR) Rate at Week 4","description":"uSFR was assessed by weighing of dental rolls soaked with saliva over 5 minutes and then procedure was repeated after 30 minutes and the average of the 2 results for flow rate was calculated.","populationDescription":"Analysis covers all participants from FAS who have at least one post-baseline uSFR assessment. The FAS is the subset of participants who were treated and had at least the baseline value of uSFR.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"gram per minute (g/min)","timeFrame":"Baseline and Week 4","groups":[{"id":"OG000","title":"MP: Placebo","description":"Participants received one injection session of overall 2.0 mL placebo matched to the volume of incobotulinumtoxinA via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 in the MP."},{"id":"OG001","title":"MP: IncobotulinumtoxinA (Xeomin) (75 Units)","description":"Participants received one injection session of overall 2.0 mL incobotulinumtoxinA containing 75 units via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 in the MP."},{"id":"OG002","title":"MP: IncobotulinumtoxinA (Xeomin) (100 Units)","description":"Participants received one injection session of overall 2.0 mL incobotulinumtoxinA containing 100 units via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 in the MP."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"73"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"0.033"},{"groupId":"OG001","value":"-0.06","spread":"0.027"},{"groupId":"OG002","value":"-0.13","spread":"0.026"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"A fixed sequence test procedure was used for the confirmatory analysis of the co-primary endpoints by comparing the least square (LS) means estimates of an mixed model repeated measurement (MMRM) model (2-sided, significance level alpha=0.05) between treatment groups in the following order:\n\n1. IncobotulinumtoxinA 100 units versus (v) Placebo\n2. IncobotulinumtoxinA 75 units v Placebo","nonInferiorityType":"SUPERIORITY","pValue":"= 0.004","statisticalMethod":"MMRM","paramType":"LS mean difference","paramValue":"-0.09","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.15","ciUpperLimit":"0.03","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.031"},{"groupIds":["OG000","OG001"],"groupDescription":"A fixed sequence test procedure was used for the confirmatory analysis of the co-primary endpoints by comparing the least square means estimates of an MMRM model (2-sided, significance level alpha=0.05) between treatment groups in the following order:\n\n1. IncobotulinumtoxinA 100 units v Placebo\n2. IncobotulinumtoxinA 75 units v Placebo","nonInferiorityType":"SUPERIORITY","pValue":"= 0.542","statisticalMethod":"MMRM","paramType":"LS mean difference","paramValue":"-0.02","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.08","ciUpperLimit":"0.04","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.03"}]},{"type":"PRIMARY","title":"MP: Participant's Global Impression of Change Scale (GICS) at Week 4","description":"The GICS was used to measure the impression of change due to treatment. The response option was a common 7-point Likert scale that ranged from -3 = very much worse to +3 = very much improved and was applicable for participant and caregiver. If the participant was not able to answer then carer's rating was to be recorded instead of participant's rating and the participant's rating was left blank.","populationDescription":"The FAS is the subset of participants who were treated and had at least the baseline value of uSFR.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 4","groups":[{"id":"OG000","title":"MP: Placebo","description":"Participants received one injection session of overall 2.0 mL placebo matched to the volume of incobotulinumtoxinA via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 in the MP."},{"id":"OG001","title":"MP: IncobotulinumtoxinA (Xeomin) (75 Units)","description":"Participants received one injection session of overall 2.0 mL incobotulinumtoxinA containing 75 units via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 in the MP."},{"id":"OG002","title":"MP: IncobotulinumtoxinA (Xeomin) (100 Units)","description":"Participants received one injection session of overall 2.0 mL incobotulinumtoxinA containing 100 units via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 in the MP."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"74"},{"groupId":"OG002","value":"74"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"0.186"},{"groupId":"OG001","value":"1.02","spread":"0.148"},{"groupId":"OG002","value":"1.25","spread":"0.144"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"A fixed sequence test procedure was used for the confirmatory analysis of the co-primary endpoints by comparing the least square means estimates of an MMRM model (2-sided, significance level alpha=0.05) between treatment groups in the following order:\n\n1. IncobotulinumtoxinA 100 units v Placebo\n2. IncobotulinumtoxinA 75 units v Placebo","nonInferiorityType":"SUPERIORITY","pValue":"= 0.002","statisticalMethod":"MMRM","paramType":"LS mean difference","paramValue":"0.58","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.22","ciUpperLimit":"0.94","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.183"},{"groupIds":["OG000","OG001"],"groupDescription":"A fixed sequence test procedure was used for the confirmatory analysis of the co-primary endpoints by comparing the least square means estimates of an MMRM model (2-sided, significance level alpha=0.05) between treatment groups in the following order:\n\n1. IncobotulinumtoxinA 100 units v Placebo\n2. IncobotulinumtoxinA 75 units v Placebo","nonInferiorityType":"SUPERIORITY","pValue":"= 0.055","statisticalMethod":"MMRM","paramType":"LS mean difference","paramValue":"0.35","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.01","ciUpperLimit":"0.71","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.181"}]},{"type":"SECONDARY","title":"MP: Change From Baseline in Unstimulated Salivary Flow (uSFR) Rate at Week 8 and 12","description":"uSFR was assessed by weighing of dental rolls soaked with saliva over 5 minutes and then procedure was repeated after 30 minutes and the average of the 2 results for flow rate was calculated.","populationDescription":"Analysis covers all participants from FAS who have at least one post-baseline uSFR assessment. The FAS is the subset of participants who were treated and had at least the baseline value of uSFR.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"g/min","timeFrame":"Baseline, Week 8 and 12","groups":[{"id":"OG000","title":"MP: Placebo","description":"Participants received one injection session of overall 2.0 mL placebo matched to the volume of incobotulinumtoxinA via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 in the MP."},{"id":"OG001","title":"MP: IncobotulinumtoxinA (Xeomin) (75 Units)","description":"Participants received one injection session of overall 2.0 mL incobotulinumtoxinA containing 75 units via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 in the MP."},{"id":"OG002","title":"MP: IncobotulinumtoxinA (Xeomin) (100 Units)","description":"Participants received one injection session of overall 2.0 mL incobotulinumtoxinA containing 100 units via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 in the MP."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"73"}]}],"classes":[{"title":"Week 8","categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.033"},{"groupId":"OG001","value":"-0.08","spread":"0.027"},{"groupId":"OG002","value":"-0.13","spread":"0.026"}]}]},{"title":"Week 12","categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.033"},{"groupId":"OG001","value":"-0.1","spread":"0.027"},{"groupId":"OG002","value":"-0.12","spread":"0.026"}]}]}]},{"type":"SECONDARY","title":"MP: Global Impression of Change Scale (GICS) at Week 1, 2, 8 and 12","description":"The GICS was used to measure the investigator's impression of change due to treatment. The response option was a common 7-point Likert scale that ranged from -3 = very much worse to +3 = very much improved and was applicable for participant and caregiver. If the participant was not able to answer then carer's rating was to be recorded instead of participant's rating and the participant's rating was left blank.","populationDescription":"The FAS is the subset of participants who were treated and had at least the baseline value of uSFR.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Week 1, 2, 8, and 12","groups":[{"id":"OG000","title":"MP: Placebo","description":"Participants received one injection session of overall 2.0 mL placebo matched to the volume of incobotulinumtoxinA via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 in the MP."},{"id":"OG001","title":"MP: IncobotulinumtoxinA (Xeomin) (75 Units)","description":"Participants received one injection session of overall 2.0 mL incobotulinumtoxinA containing 75 units via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 in the MP."},{"id":"OG002","title":"MP: IncobotulinumtoxinA (Xeomin) (100 Units)","description":"Participants received one injection session of overall 2.0 mL incobotulinumtoxinA containing 100 units via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 in the MP."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"74"},{"groupId":"OG002","value":"74"}]}],"classes":[{"title":"Week 1","categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"0.17"},{"groupId":"OG001","value":"0.73","spread":"0.138"},{"groupId":"OG002","value":"0.96","spread":"0.133"}]}]},{"title":"Week 2","categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"0.178"},{"groupId":"OG001","value":"0.91","spread":"0.143"},{"groupId":"OG002","value":"1.11","spread":"0.139"}]}]},{"title":"Week 8","categories":[{"measurements":[{"groupId":"OG000","value":"0.47","spread":"0.192"},{"groupId":"OG001","value":"1.07","spread":"0.151"},{"groupId":"OG002","value":"1.3","spread":"0.148"}]}]},{"title":"Week 12","categories":[{"measurements":[{"groupId":"OG000","value":"0.56","spread":"0.197"},{"groupId":"OG001","value":"0.98","spread":"0.156"},{"groupId":"OG002","value":"1.21","spread":"0.152"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"MP: From first injection up to first injection in EP (Week 16). EP: From first injection in EP (Week 16) up to end of study (Week 64).","description":"The investigator asked the participant for adverse events systematically at each visit. Two participants received the wrong or no dose in single EP cycles due to procedural reasons and hence were not included in the safety analyses that cover the complete EP: IncobotulinumtoxinA (Xeomin) (75 Units) arm.","eventGroups":[{"id":"EG000","title":"Placebo","description":"Participants received one injection session of overall 2.0 mL placebo matched to the volume of incobotulinumtoxinA via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 in the MP.","deathsNumAffected":0,"deathsNumAtRisk":36,"seriousNumAffected":3,"seriousNumAtRisk":36,"otherNumAffected":2,"otherNumAtRisk":36},{"id":"EG001","title":"MP: IncobotulinumtoxinA (Xeomin) (75 Units)","description":"Participants received one injection session of overall 2.0 mL incobotulinumtoxinA containing 75 units via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 in the MP.","deathsNumAffected":0,"deathsNumAtRisk":74,"seriousNumAffected":6,"seriousNumAtRisk":74,"otherNumAffected":14,"otherNumAtRisk":74},{"id":"EG002","title":"MP: IncobotulinumtoxinA (Xeomin) (100 Units)","description":"Participants received one injection session of overall 2.0 mL incobotulinumtoxinA containing 100 units via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 in the MP.","deathsNumAffected":0,"deathsNumAtRisk":74,"seriousNumAffected":9,"seriousNumAtRisk":74,"otherNumAffected":10,"otherNumAtRisk":74},{"id":"EG003","title":"EP: IncobotulinumtoxinA (Xeomin) (75 Units)","description":"Participants received overall 2.0 mL incobotulinumtoxinA containing 75 units via bilateral intraglandular injection into the parotid and submandibular glands at each of the three injection sessions in the EP.","deathsNumAffected":3,"deathsNumAtRisk":82,"seriousNumAffected":15,"seriousNumAtRisk":82,"otherNumAffected":22,"otherNumAtRisk":82},{"id":"EG004","title":"EP: IncobotulinumtoxinA (Xeomin) (100 Units)","description":"Participants received overall 2.0 mL incobotulinumtoxinA containing 100 units via bilateral intraglandular injection into the parotid and submandibular glands at each of the three injection sessions in the EP.","deathsNumAffected":2,"deathsNumAtRisk":89,"seriousNumAffected":14,"seriousNumAtRisk":89,"otherNumAffected":22,"otherNumAtRisk":89}],"seriousEvents":[{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Hypertensive crisis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Peripheral arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":89}]},{"term":"Coronary arterial stent insertion","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Medical device battery replacement","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Medical device change","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Rehabilitation therapy","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Angioplasty","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Appendicectomy","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Enterostomy","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Explorative laparotomy","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Laparotomy","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Nephrectomy","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Renal stone removal","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Ureter dilation procedure","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Ureteral stent insertion","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Hallucination","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Delusion","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":89}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Dopamine dysregulation syndrome","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":89}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Lumbar vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Rib fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Chest injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Skin abrasion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Spinal column injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Craniocerebral injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Angiogram","organSystem":"Investigations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Aortic valve stenosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Coagulopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Lower respiratory tract inflammation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Parkinson's disease","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG003","numEvents":8,"numAffected":6,"numAtRisk":82},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":89}]},{"term":"Drop attacks","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Freezing phenomenon","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Akinesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Altered state of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Dementia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Generalised tonic-clonic seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Movement disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Orthostatic intolerance","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Psychomotor hyperactivity","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Speech disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Cardiac pacemaker insertion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Gastritis erosive","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Gastrointestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Subileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Volvulus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":89}]},{"term":"Faecal vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Gastric ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Giant cell epulis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Megacolon","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Oesophageal food impaction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Hydronephrosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Urethral stenosis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":89}]},{"term":"Extravasation of urine","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Drug-induced liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Device occlusion","organSystem":"Product Issues","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Skin ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Pyuria","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Acute sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Clostridium difficile infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]}],"otherEvents":[{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":74},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":74},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":82},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":89}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":74},{"groupId":"EG002","numEvents":5,"numAffected":2,"numAtRisk":74},{"groupId":"EG003","numEvents":9,"numAffected":5,"numAtRisk":82},{"groupId":"EG004","numEvents":5,"numAffected":4,"numAtRisk":89}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":82},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":89}]},{"term":"Tooth extraction","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":74},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":82},{"groupId":"EG004","numEvents":5,"numAffected":4,"numAtRisk":89}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":74},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":74},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":82},{"groupId":"EG004","numEvents":13,"numAffected":10,"numAtRisk":89}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":74},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":74},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":82},{"groupId":"EG004","numEvents":6,"numAffected":6,"numAtRisk":89}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 19.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":74},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":74},{"groupId":"EG003","numEvents":6,"numAffected":5,"numAtRisk":82},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":89}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected."},"pointOfContact":{"title":"Public Disclosure Manager","organization":"Merz Pharmaceuticals GmbH","email":"clinicaltrials@merz.de","phone":"+49 69 1503 1"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","removedCountries":["United States"]},"conditionBrowseModule":{"meshes":[{"id":"D000012798","term":"Sialorrhea"},{"id":"D000010300","term":"Parkinson Disease"},{"id":"D000001930","term":"Brain Injuries"},{"id":"D000070642","term":"Brain Injuries, Traumatic"}],"ancestors":[{"id":"D000020734","term":"Parkinsonian Disorders"},{"id":"D000001480","term":"Basal Ganglia Diseases"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000009069","term":"Movement Disorders"},{"id":"D000080874","term":"Synucleinopathies"},{"id":"D000019636","term":"Neurodegenerative Diseases"},{"id":"D000006259","term":"Craniocerebral Trauma"},{"id":"D000020196","term":"Trauma, Nervous System"},{"id":"D000014947","term":"Wounds and Injuries"},{"id":"D000012466","term":"Salivary Gland Diseases"},{"id":"D000009059","term":"Mouth Diseases"},{"id":"D000009057","term":"Stomatognathic Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M12903","name":"Parkinson Disease","asFound":"Parkinson's Disease","relevance":"HIGH"},{"id":"M4897","name":"Brain Injuries","asFound":"Brain Injury","relevance":"HIGH"},{"id":"M628","name":"Brain Injuries, Traumatic","asFound":"Traumatic Brain Injury","relevance":"HIGH"},{"id":"M15294","name":"Sialorrhea","asFound":"Sialorrhea","relevance":"HIGH"},{"id":"M22184","name":"Parkinsonian Disorders","relevance":"LOW"},{"id":"M25293","name":"Ganglion Cysts","relevance":"LOW"},{"id":"M16048","name":"Synovial Cyst","relevance":"LOW"},{"id":"M4464","name":"Basal Ganglia Diseases","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M11719","name":"Movement Disorders","relevance":"LOW"},{"id":"M2217","name":"Synucleinopathies","relevance":"LOW"},{"id":"M21248","name":"Neurodegenerative Diseases","relevance":"LOW"},{"id":"M17375","name":"Wounds and Injuries","relevance":"LOW"},{"id":"M9039","name":"Craniocerebral Trauma","relevance":"LOW"},{"id":"M21713","name":"Trauma, Nervous System","relevance":"LOW"},{"id":"M14975","name":"Salivary Gland Diseases","relevance":"LOW"},{"id":"M11709","name":"Mouth Diseases","relevance":"LOW"},{"id":"M11707","name":"Stomatognathic Diseases","relevance":"LOW"},{"id":"T1303","name":"Chronic Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC26","name":"Wounds and Injuries"},{"abbrev":"BC07","name":"Mouth and Tooth Diseases"},{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC17","name":"Skin and Connective Tissue Diseases"},{"abbrev":"BC18","name":"Nutritional and Metabolic Diseases"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001905","term":"Botulinum Toxins"},{"id":"D000019274","term":"Botulinum Toxins, Type A"},{"id":"C000542869","term":"abobotulinumtoxinA"},{"id":"C000545476","term":"incobotulinumtoxinA"}],"ancestors":[{"id":"D000065087","term":"Acetylcholine Release Inhibitors"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000009465","term":"Neuromuscular Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"}],"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","asFound":"250","relevance":"HIGH"},{"id":"M250157","name":"abobotulinumtoxinA","asFound":"Previous","relevance":"HIGH"},{"id":"M20947","name":"Botulinum Toxins, Type A","asFound":"Previous","relevance":"HIGH"},{"id":"M250251","name":"incobotulinumtoxinA","asFound":"Afatinib","relevance":"HIGH"},{"id":"M21550","name":"Pharmaceutical Solutions","relevance":"LOW"},{"id":"M3163","name":"Acetylcholine","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"PhSol","name":"Pharmaceutical Solutions"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"}]}},"hasResults":true}